Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 764198 in primary or TRPC6 genetic focal segmental glomerulosclerosis
2025-522191-86-00Phase 3Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 37
01
Overview
Phase 3, randomised, double-blind trial in focal segmental glomerulosclerosis (FSGS) comparing BI 764198 with Placebo matching BI 764198 (2 arms). Primary endpoint: Relative change in 24-hour urine protein-to-creatinine ratio. Planned start Apr 2026; status: authorised.
02
Drugs
apecotrep
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on 2025-522191-86-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522191-86-00.